KR20200131246A - 키나제 억제제로서의 헤테로시클릭 화합물 - Google Patents

키나제 억제제로서의 헤테로시클릭 화합물 Download PDF

Info

Publication number
KR20200131246A
KR20200131246A KR1020207026424A KR20207026424A KR20200131246A KR 20200131246 A KR20200131246 A KR 20200131246A KR 1020207026424 A KR1020207026424 A KR 1020207026424A KR 20207026424 A KR20207026424 A KR 20207026424A KR 20200131246 A KR20200131246 A KR 20200131246A
Authority
KR
South Korea
Prior art keywords
formula
compound
alkylene
salt
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207026424A
Other languages
English (en)
Korean (ko)
Inventor
손 민 팜
사르바지트 샤크라바르티
자야칸스 칸카나라
브라맘 푸자라
아미트 세티
브하와나 배트
아닐 쿠마르 아가르발
산제브 소니
지윤 첸
Original Assignee
누베이션 바이오 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누베이션 바이오 인크. filed Critical 누베이션 바이오 인크.
Publication of KR20200131246A publication Critical patent/KR20200131246A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207026424A 2018-02-15 2019-02-15 키나제 억제제로서의 헤테로시클릭 화합물 Withdrawn KR20200131246A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862631437P 2018-02-15 2018-02-15
US62/631,437 2018-02-15
PCT/US2019/018244 WO2019161224A1 (en) 2018-02-15 2019-02-15 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20200131246A true KR20200131246A (ko) 2020-11-23

Family

ID=67542098

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026424A Withdrawn KR20200131246A (ko) 2018-02-15 2019-02-15 키나제 억제제로서의 헤테로시클릭 화합물

Country Status (13)

Country Link
US (2) US11174252B2 (https=)
EP (1) EP3752491A4 (https=)
JP (1) JP2021514359A (https=)
KR (1) KR20200131246A (https=)
CN (1) CN112334451A (https=)
AU (1) AU2019220746A1 (https=)
BR (1) BR112020015431A2 (https=)
CA (1) CA3089592A1 (https=)
IL (1) IL276509A (https=)
MA (1) MA51846A (https=)
MX (1) MX2020008559A (https=)
SG (1) SG11202007754UA (https=)
WO (1) WO2019161224A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
KR102797697B1 (ko) 2018-05-25 2025-04-22 에이2에이 파마수티칼스, 잉크. 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP4013743A1 (en) * 2019-08-14 2022-06-22 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US20220281859A1 (en) * 2019-08-14 2022-09-08 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN113244386A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
JP7807381B2 (ja) * 2020-03-02 2026-01-27 シロナックス リミテッド． フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
CN116249701B (zh) * 2020-10-12 2025-05-30 上海海雁医药科技有限公司 取代的二（吡啶-2-基）胺衍生物、其组合物及医药上的用途
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022169897A1 (en) * 2021-02-03 2022-08-11 Nuvation Bio Inc. Crystalline forms of a cyclin-dependent kinase inhibitor
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
WO2022236253A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236256A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236255A2 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236257A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN113264920B (zh) * 2021-05-10 2022-09-02 中国药科大学 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用
US20230000876A1 (en) * 2021-06-09 2023-01-05 Nuvation Bio Inc. Treating cancers with a cyclin-dependent kinase inhibitor
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS
WO2023205892A1 (en) * 2022-04-27 2023-11-02 Risen (Suzhou) Pharma Tech Co., Ltd. Cdk inhibitors and pharmaceutical uses thereof
KR20250004015A (ko) * 2022-04-29 2025-01-07 베이진 엘티디 사이클린 의존성 키나제 저해제로서의 치환된 7-(피리미딘-4-일)퀴놀린-4(1h)-온 화합물
WO2024022487A1 (en) * 2022-07-29 2024-02-01 Allorion Therapeutics Inc Aminoheteroaryl kinase inhibitors
CN117645604A (zh) * 2022-09-05 2024-03-05 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
EP4618755A1 (en) * 2022-11-15 2025-09-24 Larkspur Biosciences, Inc. Inhibitors and degraders of pip4k protein
WO2025007859A1 (en) * 2023-07-03 2025-01-09 Insilico Medicine Ip Limited Substituted thiazole compounds as cdk2/4/6 inhibitors and methods of use thereof
WO2025247364A1 (zh) * 2024-05-30 2025-12-04 山东先声生物制药有限公司 杂环化合物作为cdk抑制剂及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL358271A1 (pl) 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
EP1373257B9 (en) * 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1562938B1 (en) * 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
RU2008110902A (ru) 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Агонисты адренорецепторов альфа а2с
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2580213A4 (en) 2010-06-09 2013-12-25 Afraxis Holdings Inc 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
US20130252967A1 (en) 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
EP2580215A4 (en) 2010-06-10 2014-01-15 Afraxis Holdings Inc 8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
CA2807498C (en) 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2013175415A1 (en) 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US10016439B2 (en) 2014-01-31 2018-07-10 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
RU2671494C2 (ru) 2014-05-28 2018-11-01 Шанхай Фокон Фармасьютикал Ко., Лтд Некоторые ингибиторы протеинкиназы
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
KR20170032244A (ko) 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US9969719B2 (en) 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
US11225492B2 (en) 2015-12-13 2022-01-18 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN108779117B (zh) 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
WO2017133701A1 (en) 2016-02-06 2017-08-10 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CN107286180B (zh) 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
CN107286134B (zh) 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
HUE064145T2 (hu) 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
US10835535B2 (en) 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
JP7106462B2 (ja) 2016-07-01 2022-07-26 ジー１ セラピューティクス， インコーポレイテッド Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
EP3505519B1 (en) 2016-11-11 2022-01-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
ES2917377T3 (es) 2016-12-22 2022-07-08 Betta Pharmaceuticals Co Ltd Derivados de benzimidazol, procedimientos de preparación y utilizaciones de los mismos
CN107382974B (zh) 2017-06-08 2020-06-05 扬州市三药制药有限公司 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用
CA3088381A1 (en) 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2020006210A1 (en) 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
WO2020023480A1 (en) 2018-07-23 2020-01-30 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
BR112021001499A2 (pt) 2018-07-27 2021-04-27 California Institute Of Technology inibidores de cdk e usos dos mesmos
CN110835334B (zh) 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020108661A1 (zh) 2018-11-30 2020-06-04 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用

Also Published As

Publication number Publication date
US20190248774A1 (en) 2019-08-15
JP2021514359A (ja) 2021-06-10
AU2019220746A1 (en) 2020-08-27
EP3752491A4 (en) 2021-12-01
US11174252B2 (en) 2021-11-16
IL276509A (en) 2020-09-30
US20230062022A1 (en) 2023-03-02
EP3752491A1 (en) 2020-12-23
SG11202007754UA (en) 2020-09-29
WO2019161224A1 (en) 2019-08-22
CA3089592A1 (en) 2019-08-22
CN112334451A (zh) 2021-02-05
MA51846A (fr) 2021-04-21
BR112020015431A2 (pt) 2020-12-08
MX2020008559A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
US11174252B2 (en) Heterocyclic compounds as kinase inhibitors
KR102578325B1 (ko) Usp30 억제제로서의 1-시아노-피롤리딘 화합물
EP2424859B1 (en) Inhibitors of pi3 kinase and / or mtor
JP5241834B2 (ja) プロテインキナーゼ阻害剤としての複素環アミド化合物
AU2015323572B2 (en) Novel compounds
US20220347187A1 (en) Heterocyclic compounds as kinase inhibitors
JP7572353B2 (ja) トリアゾロ－ピリミジン化合物およびそれらの使用
AU2010254806A1 (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JP2010529195A (ja) プロテインキナーゼの阻害剤としてのイミダゾピラジン
KR20210046714A (ko) 피라진 화합물 및 이의 용도
US20220273659A1 (en) Heterocyclic compounds as kinase inhibitors
CA3219002A1 (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
HK40045721A (en) Heterocyclic compounds as kinase inhibitors
RU2802866C9 (ru) Соединения триазоло-пиримидина и их применение
RU2802866C2 (ru) Соединения триазоло-пиримидина и их применение
EP4466265A1 (en) Deoxycytidine kinase inhibitors
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK1167862B (en) Inhibitors of pi3 kinase and / or mtor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202